Stockscreener 앱 받기
21.37
0.05%
-0.010
시간 외 거래:
21.37
전일 마감가:
$21.38
열려 있는:
$21.38
하루 거래량:
1.81M
Relative Volume:
0.43
시가총액:
$2.21B
수익:
$158.18M
순이익/손실:
$-107.32M
주가수익비율:
-20.51
EPS:
-1.0421
순현금흐름:
$-107.58M
1주 성능:
+0.28%
1개월 성능:
+95.52%
6개월 성능:
+219.91%
1년 성능:
+158.09%
1일 변동 폭
$21.36
$21.41
1주일 범위
$21.29
$21.44
52주 변동 폭
$5.635
$21.44
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
명칭
Day One Biopharmaceuticals Inc
전화
650 484-0899
주소
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Compare DAWN vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
21.37 | 2.21B | 158.18M | -107.32M | -107.58M | -1.0421 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2026-01-13 | 재개 | TD Cowen | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-10-09 | 재확인 | Needham | Buy |
| 2024-08-01 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2024-04-24 | 재확인 | Needham | Buy |
| 2023-04-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-02-08 | 개시 | CapitalOne | Overweight |
| 2023-02-03 | 개시 | Oppenheimer | Perform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-12-05 | 개시 | Goldman | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
모두보기
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
GLAZER CAPITAL, LLC Acquires Significant Stake in Day One Biopha - GuruFocus
Servier (DAWN) plans tender offer under March 6, 2026 merger agreement - Stock Titan
Aug Breakouts: Will Day One Biopharmaceuticals Inc stock go up in YEAR2026 Intraday Action & High Conviction Buy Zone Alerts - baoquankhu1.vn
Day One Biopharmaceuticals stock hits 52-week high at $21.44 By Investing.com - Investing.com Australia
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year HighShould You Buy? - MarketBeat
Day One Biopharmaceuticals stock hits 52-week high at $21.44 - Investing.com
Glazer Capital (NASDAQ: DAWN) reports 5.6M-share, 5.44% stake - Stock Titan
Take Profit: Is Day One Biopharmaceuticals Inc a strong growth stockStock Surge & AI Driven Stock Reports - baoquankhu1.vn
Day One Biopharmaceuticals reiterates $225M–$250M OJEMDA revenue target as pipeline expands with Emi-Le integration - MSN
Trading Action: What are the future prospects of Day One Biopharmaceuticals IncRisk Management & AI Forecasted Stock Moves - baoquankhu1.vn
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
(DAWN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Mak Capital One LLC Invests $10.21 Million in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Algert Global LLC Buys 411,000 Shares of Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - MSN
DAWN stock jumps 66% on $2.5B buyout offer from Servier - MSN
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? - Sahm
Servier All Cash Deal Reframes Day One Biopharmaceuticals Valuation Story - Sahm
Servier Acquires Day One Biopharmaceuticals for $2.5B, Betting on Tovorafenib and the Pediatric Glioma Frontier - Oncodaily
symbol__ Stock Quote Price and Forecast - CNN
HC Wainwright & Co. downgrades Day One Biopharmaceuticals (DAWN) - MSN
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? – Company Announcement - Financial Times
The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning the Merger—DAWN, SEM, FONR, and EWCZ - Carroll County Mirror-Democrat
Day One Biopharmaceuticals gains amid takeover speculation - MSN
A Look At Day One Biopharmaceuticals (DAWN) Valuation After Recent Share Price Momentum - Yahoo Finance
EDGAR Filing Documents for 0001193125-24-108544 - SEC.gov
This VICI Properties Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday - Benzinga
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Neutral" Rating at JPMorgan Chase & Co. - MarketBeat
JPMorgan downgrades Day One Biopharmaceuticals stock rating on Servier acquisition - Investing.com Canada
Servier to acquire Day One Biopharmaceuticals for $2.5 billion - Investing.com Nigeria
Day One Biopharmaceuticals Acquires Mersana Therapeutics: Key Financial Details, Purchase Price, and Pro Forma Impact - Minichart
This Day One Biopharmaceuticals Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Day One Biopharmaceuticals' (DAWN) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
Day One Biopharma : DAWN - 24/7 Wall St.
Day One Biopharmaceutical (DAWN) Downgraded to Neutral by HC Wai - GuruFocus
Day One (DAWN) soars 100% on $2.5-billion merger - MSN
Are DAWN and TALK Obtaining Fair Deals for their Shareholders? - Finviz
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now - TechStock²
Day One (DAWN) climbs to 3-year high on $2.5-billion merger - MSN
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier - The Globe and Mail
DAWN Stock Downgraded by Wedbush with Price Target Adjustment | - GuruFocus
Wedbush Reaffirms Neutral Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen - MarketBeat
Servier acquires International Biotech's Day One for USD2.5 billion - marketscreener.com
Day One Biopharma Earnings Call Highlights Ojemda Surge - The Globe and Mail
Day One (DAWN) Soars 100% on $2.5-Billion Merger - Yahoo Finance
Top Small Cap Stocks To Add to Your WatchlistMarch 7th - MarketBeat
Key deals this week: Diana Shipping, Day One Biopharmaceuticals, Hudbay Minerals and more - Seeking Alpha
Pharmaceutical Stocks To ResearchMarch 7th - MarketBeat
Day One Biopharmaceuticals Inc (DAWN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):